Chronic kidney disease means your kidneys have been losing function for more than three months. One in seven American adults has it. Nine out of ten of them do not know.
It produces no symptoms until it is advanced. By the time you feel it, most of the function is gone and does not come back.
Two numbers define your disease
eGFR estimates how much filtering capacity remains. Below 60 for three months is chronic kidney disease.
Albuminuria — measured as a urine albumin-to-creatinine ratio — measures damage. It rises years before eGFR falls. A ratio above 30 mg/g is abnormal even with a perfectly normal eGFR.
Both matter, and either alone will mislead you. Two patients with an identical eGFR of 45 face entirely different futures depending on whether their albuminuria is 10 or 800. The guidelines stage the disease on both axes for exactly this reason.
| Stage | eGFR (mL/min) | Kidney function | What it means | How often to check |
|---|---|---|---|---|
| 1 | 90 + | Normal, with kidney damage | Protect function; treat the cause | Yearly |
| 2 | 60–89 | Mildly reduced | Monitor; control BP and diabetes | Yearly |
| 3a–3b | 30–59 | Moderately reduced | Nephrology often involved; slow progression | Every 6–12 months |
| 4 | 15–29 | Severely reduced | Plan ahead; protect remaining function | Every 3–6 months |
| 5 | Below 15 | Kidney failure | Dialysis or transplant discussion | Every 1–3 months |
Those intervals are a general guide. Your physician adjusts them based on how much protein is in your urine and how quickly your eGFR has changed.
If you have diabetes or hypertension and nobody has checked your urine albumin, that is the gap. Annual albumin screening in diabetes is standard of care and is skipped constantly. It is among the highest-yield tests in medicine and among the least ordered.
The part most patients are never told
For decades the honest answer was that we could slow chronic kidney disease modestly and mostly waited for dialysis.
That changed, and it changed recently.
SGLT2 inhibitors — dapagliflozin, empagliflozin — reduce progression to kidney failure by roughly a third. They work in patients with diabetes and in patients without it. They were developed as diabetes drugs and turned out to be the most important kidney drugs in a generation.
Finerenone, a non-steroidal mineralocorticoid antagonist, reduces kidney and cardiovascular events on top of what an ACE inhibitor or ARB already delivers.
GLP-1 receptor agonists — semaglutide and others — now show kidney benefit in their own right.
ACE inhibitors and ARBs remain foundational and are still underdosed, or stopped over a modest creatinine rise that was never a reason to stop them.
| Therapy | What it does for your kidneys |
|---|---|
| SGLT2 inhibitors (dapagliflozin, empagliflozin) | Slow the decline toward kidney failure and protect the heart — the biggest advance in decades |
| Finerenone | Lowers kidney and cardiovascular risk in diabetic kidney disease |
| GLP-1 agonists (semaglutide) | Emerging kidney protection, plus better glucose and weight control |
| ACE inhibitors / ARBs | Foundational — ease pressure inside the kidney's filters; still routinely underdosed |
These are additive. A patient on all the appropriate agents has a materially different trajectory than a patient on one, and the gap between what is available and what is prescribed is wide.
Ask what you are on, and ask why you are not on the rest.
Why creatinine rising after starting a drug is usually fine
An ACE inhibitor, an ARB, or an SGLT2 inhibitor commonly produces a small rise in creatinine in the first weeks. It reflects a change in pressure inside the glomerulus, not injury.
A rise up to roughly thirty percent is expected and the drug should continue. Stopping it costs the patient the exact therapy that was protecting the kidney.
This happens constantly. It is one of the most common and most consequential errors in the care of kidney disease, and it is made by well-meaning physicians reading a number in isolation.
What else has to be managed
Chronic kidney disease is not one problem. Blood pressure, below 130/80 for nearly everyone. Anemia, which begins as an iron problem long before it becomes an erythropoietin problem. Bone and mineral disorder, where phosphorus additives in processed food matter more than cheese. Metabolic acidosis, where a bicarbonate of 19 looks minor and correcting it slows progression. Potassium, which should be managed around the kidney-protective drugs rather than by stopping them.
Cardiovascular disease, because most people with chronic kidney disease die of their heart before they ever reach dialysis.
Each of these is treatable. Each is routinely under-addressed.
How long can you live with chronic kidney disease?
It is the question patients ask most and say out loud least. The honest answer depends on the stage at diagnosis, how much protein is in the urine, and above all how well blood pressure and diabetes are controlled.
Two things put it in perspective. Most people with stage 1 to 3 disease never reach kidney failure, and the disease stays stable for years or decades when it is treated. And in chronic kidney disease the larger threat is usually the heart, not the kidney — which is why treatment covers cholesterol, weight, smoking, and blood pressure rather than the kidney alone.
A chronic kidney disease (CKD) diagnosis is not a sentence. It is information that arrived in time to change the outcome.
Which tests to ask for, and how often
If you have diabetes, high blood pressure, or a family history of kidney disease, two tests are worth asking for every year even when you feel completely well.
- Serum creatinine with a calculated eGFR — how much your kidneys are filtering.
- Urine albumin-to-creatinine ratio (ACR) — detects protein in the urine, usually the first sign of damage, sometimes years before eGFR starts to fall.
Many labs report creatinine without calculating eGFR, and will not measure urine albumin unless someone asks. Ask for both by name. And keep your results: the trend across years says far more than any single test.
Planning, not waiting
If kidney failure is coming, the difference between planning at an eGFR of 20 and arriving in an emergency room at an eGFR of 6 is enormous.
A fistula takes three to six months to mature. A transplant evaluation can begin before dialysis ever starts — and a preemptive transplant, done before the first dialysis session, produces better outcomes than one done after.
Patients who plan early keep every option. Patients who arrive in crisis get a catheter in the neck.
What we do
Stage the disease on eGFR and albuminuria together, and track the trajectory rather than a single value.
Get you on the full complement of therapy your kidneys warrant — and keep you on it, managing potassium and creatinine around the drugs instead of abandoning them.
Find the treatable cause, because a substantial fraction of chronic kidney disease is not simply diabetes and hypertension.
Manage the complications that shorten life before the kidney ever fails.
And plan, early, so that whatever comes is a decision you made rather than an emergency you survived.
If your eGFR is under 60, your albumin-to-creatinine ratio is above 30, or you have diabetes or hypertension and have never had either checked — that is the appointment worth making.